For example, the Src inhibitor Dasatinib showed acceptable tolerability in a Phase II trial in metastatic breast cancer patients [76], while monotherapy with Src inhibitors (e.g., Saracatinib) demonstrated limited efficacy in hormone-receptor negative metastatic disease [77]. This evidence concerns the gene SRC and metastatic neoplasm.